Bristol Myers Squibb Announces LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination Significantly Improves Progression-Free Survival vs. Opdivo in Patients with Previously Untreated Metastatic or Unresectable Melanoma Biotech Investing
Four-Year Data from Phase 3 CheckMate -227 Trial Show Durable, Long-Term Survival with Opdivo Plus Yervoy in Patients with Non-Small Cell Lung Cancer with PD-L1 Expression ?1% Biotech Investing
Lobe Sciences Secures Production and Supply Agreement for Vitamind Consumer Packaged Goods Products Cannabis Investing News
AbbVie to Showcase Breadth of Oncology Portfolio and Pipeline at the 2021 ASCO and EHA Annual Congresses Biotech Investing
Agenus and Bristol Myers Squibb Announce Exclusive Global License for Agenus' Anti-TIGIT Bispecific Antibody Program Biotech Investing
DEADLINE TODAY: The Schall Law Firm Reminds Investors of Class Action Lawsuit Against BELLUS Health Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Biotech Investing
BLU Final Deadline Today: Rosen, Trusted Investor Counsel, Encourages BELLUS Health Inc. Investors to Secure Counsel Before Important May 17 Deadline in Securities Class Action - BLU Biotech Investing
Abbott Receives CE Mark for Navitor, the Latest-Generation Transcatheter Aortic Valve Implantation System to Treat Aortic Stenosis Medical Device Investing
Gabrielle Union-Wade Joins 'Don't Skip' Campaign to Encourage Doctor Well-Visits and Recommended Vaccinations Pharmaceutical Investing
